179 related articles for article (PubMed ID: 16270214)
1. Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer?
Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Scheiderbauer J; Machulla HJ; Dittmann H; Vonthein R; Bares R
Eur J Nucl Med Mol Imaging; 2006 Mar; 33(3):263-9. PubMed ID: 16270214
[TBL] [Abstract][Full Text] [Related]
2. Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors.
Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Scheiderbauer J; Budach W; Kotzerke J; Bares R
Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):54-9. PubMed ID: 16896660
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer.
Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Langen HJ; Bares R
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):463-71. PubMed ID: 17103167
[TBL] [Abstract][Full Text] [Related]
4. Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer.
Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Budach W; Dittmann H; Langen HJ; Bares R
Lung Cancer; 2007 Feb; 55(2):165-71. PubMed ID: 17129635
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
Higashi K; Ueda Y; Arisaka Y; Sakuma T; Nambu Y; Oguchi M; Seki H; Taki S; Tonami H; Yamamoto I
J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer.
Hellwig D; Gröschel A; Graeter TP; Hellwig AP; Nestle U; Schäfers HJ; Sybrecht GW; Kirsch CM
Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):13-21. PubMed ID: 16151765
[TBL] [Abstract][Full Text] [Related]
7. Determination of the prognostic value of [(18)F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer.
Jeong HJ; Min JJ; Park JM; Chung JK; Kim BT; Jeong JM; Lee DS; Lee MC; Han SK; Shim YS
Nucl Med Commun; 2002 Sep; 23(9):865-70. PubMed ID: 12195091
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
9. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group.
Vansteenkiste JF; Stroobants SG; Dupont PJ; De Leyn PR; Verbeken EK; Deneffe GJ; Mortelmans LA; Demedts MG
J Clin Oncol; 1999 Oct; 17(10):3201-6. PubMed ID: 10506619
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
[TBL] [Abstract][Full Text] [Related]
11. Limited Prognostic Value of SUV max Measured by F-18 FDG PET/CT in Newly Diagnosed Small Cell Lung Cancer Patients.
Kim SJ; Chang S
Oncol Res Treat; 2015; 38(11):577-85. PubMed ID: 26599271
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG uptake by primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small cell lung cancer: analysis of a multicenter study.
Higashi K; Ito K; Hiramatsu Y; Ishikawa T; Sakuma T; Matsunari I; Kuga G; Miura K; Higuchi T; Tonami H; Yamamoto I
J Nucl Med; 2005 Feb; 46(2):267-73. PubMed ID: 15695786
[TBL] [Abstract][Full Text] [Related]
13. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer.
Borst GR; Belderbos JS; Boellaard R; Comans EF; De Jaeger K; Lammertsma AA; Lebesque JV
Eur J Cancer; 2005 Jul; 41(11):1533-41. PubMed ID: 15953716
[TBL] [Abstract][Full Text] [Related]
14. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
[TBL] [Abstract][Full Text] [Related]
15. Limited prognostic value of dual time point F-18 FDG PET/CT in patients with early stage (stage I & II) non-small cell lung cancer (NSCLC).
Kim SJ; Kim YK; Kim IJ; Kim YD; Lee MK
Radiother Oncol; 2011 Jan; 98(1):105-8. PubMed ID: 21159395
[TBL] [Abstract][Full Text] [Related]
16. Intra-tumour 18F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging.
Dong X; Wu P; Sun X; Li W; Wan H; Yu J; Xing L
J Med Imaging Radiat Oncol; 2015 Jun; 59(3):338-45. PubMed ID: 25708154
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG uptake as a biologic factor predicting outcome in patients with resected non-small-cell lung cancer.
Zhang ZJ; Chen JH; Meng L; Du JJ; Zhang L; Liu Y; Dai HH
Chin Med J (Engl); 2007 Jan; 120(2):125-31. PubMed ID: 17335654
[TBL] [Abstract][Full Text] [Related]
18. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of volume-based 18F-FDG PET/CT parameter in patients with surgically resected non-small cell lung cancer. Comparison with immunohistochemical biomarkers.
Lee JY; Choi JY; Heo JH; Han J; Jang SJ; Kim K; Kim J; Shim YM; Kim BT
Nuklearmedizin; 2016; 55(1):7-14. PubMed ID: 26875430
[TBL] [Abstract][Full Text] [Related]
20. Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours.
Brenner W; Friedrich RE; Gawad KA; Hagel C; von Deimling A; de Wit M; Buchert R; Clausen M; Mautner VF
Eur J Nucl Med Mol Imaging; 2006 Apr; 33(4):428-32. PubMed ID: 16404595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
